Current therapeutic options for major depressive disorder (MDD) and bipolar disorder (BD)
are associated with a lag of onset that can prolong distress and impairment for patients, and …

Current pharmacotherapies for major depressive disorder (MDD) have a distinct lag of onset
that can prolong distress and impairment for patients, and realworld effectiveness trials …

Major depressive disorder (MDD) is a chronic, recurring, and debilitating mental illness that
is the most common mood disorder in the United States. It has been almost 50 years since …

Current pharmacotherapies for major depressive disorder (MDD) and bipolar depression
(BDep) have a distinct lag of onset that can generate great distress and impairment in …

Major depressive disorder (MDD) is a common, recurrent mental illness that affects millions
of people worldwide. Accumulating evidence suggests that the N-methyl-D-aspartate …

Introduction: Current antidepressant therapies exhibit low therapeutic efficiency and delayed
onset of antidepressant action. Thus, the search for better acting agents is a continuous …

Introduction: Mood disorders, including depression, are becoming increasingly prevalent in
the developed world. Furthermore, treatment of depression therapeutics, mainly influencing …

In this article, we first review a study showing that the N-methyl-d-aspartate (NMDA) receptor
antagonist ketamine leads to rapid, robust, and relatively sustained antidepressant effects in …

There is accumulating evidence demonstrating that dysfunction of glutamatergic
neurotransmission, particularly via N-methyl-d-aspartate (NMDA) receptors, is involved in …

Over the past 20 years, converging lines of evidence have both linked glutamatergic
dysfunction to the pathophysiology of depression and demonstrated that the glutamatergic …